Loading
A phase 2 trial of Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) is a phase 2 interventional study registered as NCT05557591 by Regeneron Pharmaceuticals, with 51 participants enrolled, started 2023-04-21 and due to reach its primary completion in 2028-01-26. Interventions recorded: BNT116, Cemiplimab. Conditions listed: Advanced Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Regeneron, PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Regeneron, PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.